Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain
Crossref DOI link: https://doi.org/10.1007/s40261-016-0402-2
Published Online: 2016-05-03
Published Print: 2016-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Vennera, María del Carmen
Valero, Antonio
Uría, Estefany
Forné, Carles
Picado, César
Funding for this research was provided by:
Novartis Pharmaceuticals Spain
Text and Data Mining valid from 2016-05-03